CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington's intensifying drug-pricing push

In an open letter to Congress, the heads of major biopharma companies including Eli Lilly, AbbVie, Bristol Myers Squibb, Biogen, GlaxoSmithKline and many more wrote that one proposal in particular—allowing Medicare to negotiate drug prices—would "threaten patients' access to medicines and sacrifice future medical advances."